MTI-301 a SCD1 inhibitor for the treatment of nash
Ended Project Grant Awarded Last action
- Award ID
- R41DK131705
- Recipient
-
Modulation Therapeutics, Inc. UEI FPRRYGJGEHB1
- Awarding agency
-
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $344,919
Award facts
- Assistance listing
- 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research
- Completion date
- Place of performance
- West Virginia, USA
Award details come from USAspending.gov.
Description
- Abstract
- Non-alcoholic fatty liver disease (nafld) is one of the most common liver diseases in children and adults associated with diet-associated hepatic lipid accumulation (steatosis), and is a common hepatic manifestation of obesity and metabolic syndromes including diabetes. Modulation therapeutics is developing a stearoyl- coenzyme a desaturase-1 (SCD1) inhibitor for the treatment of nafld and nash. The novel lead molecule referred to as MTI-301 is orally bioavailable and well-tolerated. Pilot data with MTI-301 in mice FED a western high FAT diet attenuated the liver steatosis and significantly improved liver function. We will leverage data generated in pre-clinical models of both a western high FAT diet as well as a methionine-choline-deficient (MCD) diet to test the efficacy of MTI-301 as anti-steatosis single agent treatment option. In this proposal we will test our central hypothesis that sustained inhibition of SCD1 with the clinical lead molecule, MTI-301 as a single agent, will attenuate hepatic lipogenesis, reduce triglyceride accumulation, as well as reduce the liver injury, in diet-induced rodent models of nafld/nash. To test our hypothesis in specific aim 1 we will utilize a well-established murine model of nafdl and nash and treat with different doses of MTI-301 in specific aim 2, we will evaluate the combination therapy of MTI-301 with pioglitazone, an anti-diabetic drug. Since obesity and metabolic syndromes contribute to the development of liver steatosis, we expect the combination to be reduce the liver dysfunction significantly. Prevention or reversal of liver steatosis is a significant therapeutic goal which can prevent multiple secondary metabolic disorders which increases morbidity and mortality worldwide.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $344,919 |
Quick answers
Who received award R41DK131705?
R41DK131705 was awarded to Modulation Therapeutics, Inc. by National Institute of Diabetes and Digestive and Kidney Diseases (National Institutes of Health) on May 1, 2023.
How much is award R41DK131705 worth?
$344,919 has been obligated on R41DK131705.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award